| 摘要 |
Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:CORE MOIETY-(R)jincluding resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(1-10), alkyl, C(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I:-(CH2)n-C-(R1)p,Iwherein n is an integer from three to twenty; p is two or three; R1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C(1-10) alkyl, C(1-10) alkoxy, C(2-10) alkenyl, cyclic or heterocyclic group; =N-OR2, R2 being hydrogen or a substitute or unsubstituted C(1-10) alkyl, C(2-10) alkenyl, cyclic or heterocyclic group; and -(CH2)s-C(R3)t (wherein s is zero or an integer from one to ten, t is two or three, R3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C(1-10) alkyl, C(1-10) alkoxy, C(2-10) alkenyl, cyclic or heterocyclic group, or =N-OR2, R2 being defined above). At least one R1 or one R3 is =N-OR2, p or t corresponding to the at least one R1 or one R3 is two, and a second R1 or second R3, bonded to the same -C as the at least one R1 or one R3, is other than =N-OR2. These disclosed compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.
|
